About US
Contact us
-
J&J chief Gorsky, in China for official summit, straddles Trump's globalism divideAmid uncertainty for pharma as President Donald Trump embarks on his quest of putting “America First,” Johnson & Johnson CEO Alex Gorsky played down the potential falloutfor his company during a C2017/3/27
-
Pierre Fabre and H-Immune to develop new cancer immunotherapiesFrench pharmaceutical company Pierre Fabre and H-Immune have entered a strategic research partnership to develop new cancer immunotherapies. The partnership will use H-Immune’s In Vitro Immunization2017/3/24
-
Emergent signs $100m BARDA contract to deliver BioThraxUS-based Emergent BioSolutions has signed a $100m contract with the Biomedical Advanced Research and Development Authority (BARDA) to deliver BioThrax (Anthrax Vaccine Adsorbed) to the Strategic Natio2017/3/24
-
PCC acquires Intrathecal Therapy business from Mallinckrodt for $203mPiramal’s wholly owned Critical Care subsidiary in the UK PCC has completed its previously announced acquisition of Intrathecal Therapy business from Mallinckrodt for $203m. PCC is engaged in the fie2017/3/23
-
Bellus Health agrees to sell Thallion to US firm Taro PharmaceuticalsBellus Health has signed an agreement to sell its wholly owned subsidiary Thallion Pharmaceuticals, including all the rights to the Shigamab drug candidate to US-based Taro Pharmaceuticals. Taro will2017/3/23
-
UK NICE Board approves changes to drug evaluation processThe UK National Institute for Health and Care Excellence (NICE) board has approved changes to the drug evaluation process. The introduction of a new fast-track option for appraising treatments, a bud2017/3/22
-
GSK submits application to FDA for expanded indication of influenza vaccineUK's GlaxoSmithKline (GSK) has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for expanded indication of its influenza vaccine, Fluarix Quad2017/3/22
-
FDA grants orphan drug designation to Boehringer Ingelheim’s antibody BI 836858The US Food and Drug Administration (FDA) has granted orphan drug designation to Boehringer Ingelheim’s anti-CD33 monoclonal antibody, BI 836858, which is being investigated in the treatment of myelod2017/3/21
-
FDA grants IND clearance for Servier’s UCART19 to treat relapsed / refractory ALLThe US Food and Drug Administration (FDA) has granted an investigational new drug (IND) clearance to Servier to proceed with the clinical development of UCART19 in the country. UCART19 is an allogene2017/3/21
-
Pharnext and Galapagos partner to generate new pipeline of synergistic drug combinationsFrench biopharmaceutical company Pharnext has announced a research and development (R&D) agreement with Galapagos to generate a new pipeline of synergistic drug combinations. The agreement will i2017/3/20